Moncy Mathew
Impact in
- Infectious Diseases top 0.2%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Modeling and Simulation top 1%
- COVID-19 epidemiological studies
Papers in
-
- COVID-19 Clinical Research Studies 6
- SARS-CoV-2 and COVID-19 Research 4
-
- Stroke Rehabilitation and Recovery 1
- Journals
- The Lancet (8 papers)JAMA (2 papers)JCI Insight (1 paper)Clinical Infectious Diseases (1 paper)JAMA Oncology (1 paper)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Moncy Mathew
13 papers receiving 5.9k citations
Moncy Mathew's Hit Papers
Peers
Comparison fields: 5 of 127
- Infectious Diseases 4.3k
- Modeling and Simulation 292
- Health 348
- Rehabilitation 131
- Toxicology 89
Countries citing papers authored by Moncy Mathew
This map shows the geographic impact of Moncy Mathew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moncy Mathew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moncy Mathew more than expected).
Fields of papers citing papers by Moncy Mathew
This network shows the impact of papers produced by Moncy Mathew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moncy Mathew. The network helps show where Moncy Mathew may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Hit paper breakdown → | 2020 | 3698 |
| 2 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Hit paper breakdown → | 2021 | 894 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 6 | 2018 | 217 | |
| 7 | 2021 | 213 | |
| 8 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 9 | 2023 | 46 | |
| 10 | 2022 | 38 | |
| 11 | 2023 | 34 | |
| 12 | 2022 | 16 | |
| 13 | 2025 | 5 |
About Moncy Mathew
Moncy Mathew is a scholar working on Infectious Diseases, Rehabilitation, Nutrition and Dietetics, Pulmonary and Respiratory Medicine and Epidemiology, having authored 13 papers that have together received 6.2k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (6 papers), SARS-CoV-2 and COVID-19 Research (4 papers), Prostate Cancer Treatment and Research (1 paper), Acute Ischemic Stroke Management (1 paper), Vitamin C and Antioxidants Research (1 paper) and Stroke Rehabilitation and Recovery (1 paper). The work is most often cited by research in Infectious Diseases (4.3k citations), Modeling and Simulation (292 citations), Health (348 citations), Rehabilitation (131 citations) and Toxicology (89 citations). Moncy Mathew has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Their work appears in journals such as The Lancet, JAMA, JCI Insight, Clinical Infectious Diseases and JAMA Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.